In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: Mechanisms of resistance and antimicrobial exposure

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3004-3013

  Solé, Mar ^a   Fàbrega, Anna ^a   Cobos Trigueros, Nazaret ^b   Zamorano, Laura ^c   Ferrer Navarro, Mario ^a   Ballesté Delpierre, Clara ^a   Reustle, Anna ^a   Castro, Pedro ^b   Nicolás, José Maria ^b   Oliver, Antonio ^c   Martínez, José Antonio ^b   Vila, Jordi ^a,b  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG DETERMINATION; DRUG EXPOSURE; DRUG MECHANISM; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IN VIVO STUDY; INTENSIVE CARE UNIT; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PATIENT SELECTION; PREVALENCE; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; CLASSIFICATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EVOLUTION; MOLECULAR TYPING; PSEUDOMONAS INFECTIONS; PULSED FIELD GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EVOLUTION, MOLECULAR; GENE EXPRESSION PROFILING; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84949034611     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv228     Document Type: Article

References (53)

1. Hanberger H, Garcia-Rodriguez JA, Gobernado M et al. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281: 67-71.
2. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25: 825-31.
3. Boyer A, Doussau A, Thiebault R et al. Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment. Crit Care 2011; 15: R55.
4. Venier AG, Leroyer C, Slekovec C et al. Risk factors for Pseudomonas aeruginosa acquisition in intensive care units: a prospective multicentre study. J Hosp Infect 2014; 88: 103-8.
5. Glupczynski Y, Delmee M, Goossens H et al. Distribution and prevalence of antimicrobial resistance among Gram-negative isolates in intensive care units (ICU) in Belgian hospitals between 1996 and 1999. Acta Clin Belg 2001; 56: 297-306.
6. Obritsch MD, Fish DN, MacLaren R et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48: 4606-10.
7. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
8. Balasubramanian D, Kumari H, Mathee K. Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator. Pathog Dis 2014; 73: 1-15.
9. Juan C, Macia MD, Gutierrez O et al. Molecular mechanisms of ß-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2005; 49: 4733-8.
10. Moya B, Beceiro A, Cabot G et al. Pan-ß-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 2012; 56: 4771-8.
11. Juan C, Moya B, Perez JL et al. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level ß-lactam resistance involves three AmpD homologues. Antimicrob Agents Chemother 2006; 50: 1780-7.
12. Masuda N, Sakagawa E, Ohya S et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-7.
13. Poole K, Tetro K, Zhao Q et al. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 1996; 40: 2021-8.
14. Cao L, Srikumar R, Poole K. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol Microbiol 2004; 53: 1423-36.
15. Sobel ML, Hocquet D, Cao L et al. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 1782-6.
16. Poole K, Gotoh N, Tsujimoto H et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996; 21: 713-24.
17. Llanes C, Hocquet D, Vogne C et al. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48: 1797-802.
18. Kiser TH, Obritsch MD, Jung R et al. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy 2010; 30: 632-8.
19. Kohler T, Epp SF, Curty LK et al. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999; 181: 6300-5.
20. Maseda H, Saito K, Nakajima A et al. Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett 2000; 192: 107-12.
21. Sobel ML, Neshat S, Poole K. Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol 2005; 187: 1246-53.
22. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34: 52-7.
23. Kohler T, Michea-Hamzehpour M, Epp SF et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43: 424-7.
24. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998; 4: 257-61.
25. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates frombloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011; 55: 1906-11.
26. Durmaz R, Otlu B, Koksal F et al. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 2009; 62: 372-7.
27. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
28. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-64.
29. Oh H, Stenhoff J, Jalal S et al. Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microb Drug Resist 2003; 9: 323-8.
30. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47: 247-50.
31. Pai H, Kim J, Kim J et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-4.
32. El Amin N, Giske CG, Jalal S et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005; 113: 187-96.
33. Riera E, Cabot G, Mulet X et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011; 66: 2022-7.
34. Kumari H, Balasubramanian D, Zincke D et al. Role of Pseudomonas aeruginosa AmpR on ß-lactam and non-ß-lactam transient cross-resistance upon pre-exposure to subinhibitory concentrations of antibiotics. J Med Microbiol 2014; 63: 544-55.
35. Vogne C, Aires JR, Bailly C et al. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 1676-80.
36. Jeannot K, Elsen S, Kohler T et al. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 2008; 52: 2455-62.
37. Cabot G, Bruchmann S, Mulet X et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014; 58: 3091-9.
38. Bayani M, Siadati S, Rajabnia R et al. Drug resistance of Pseudomonas aeruginosa and Enterobacter cloacae isolated from ICU, Babol, Northern Iran. Int J Mol Cell Med 2013; 2: 204-9.
39. Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008; 52: 1430-7.
40. Riou M, Carbonnelle S, Avrain L et al. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int J Antimicrob Agents 2010; 36: 513-22.
41. Grohs P, Kerneis S, Sabatier B et al. Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother 2014; 69: 786-9.
42. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I ß-lactamases. J Antimicrob Chemother 1990; 25: 199-208.
43. Knapp CC, Sierra-Madero J, Washington JA. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I ß-lactamase. Diagn Microbiol Infect Dis 1989; 12: 511-5.
44. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC ß-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40: 297-305.
45. Henrichfreise B, Wiegand I, Luhmer-Becker I et al. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother 2007; 51: 3642-9.
46. Morero NR, Monti MR, Argarana CE. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob Agents Chemother 2011; 55: 3668-76.
47. Tam VH, Ledesma KR, Schilling AN et al. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis 2009; 64: 427-33.
48. Srikumar R, Paul CJ, Poole K. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 2000; 182: 1410-4.
49. Ziha-Zarifi I, Llanes C, Kohler T et al. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43: 287-91.
50. Jalal S,WretlindG, GotohNet al. Rapid identification ofmutations in amultidrug efflux pump in Pseudomonas aeruginosa. APMIS 1999; 107: 1109-16.
51. Monti MR, Morero NR, Miguel V et al. nfxB as a novel target for analysis of mutation spectra in Pseudomonas aeruginosa. PLoS One 2013; 8: e66236.
52. Caughlan RE, Jones AK, Delucia AM et al. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the Gram-negative pathogen Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56: 17-27.
53. Bruchmann S, Dotsch A, Nouri B et al. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 2013; 57: 1361-8.